ホーム › 転移性癌 › ミズーリ州 › Kansas City
Kansas City、MOにおける転移性癌の臨床試験
Kansas Cityとその周辺地域（約30マイル以内）の拠点で、転移性癌に関する15件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
被験者募集中第1相
- St. Lukes Hospital of Kansas City, Kansas City
A Study of ASP3082 in Adults With Advanced Solid Tumors
被験者募集中第1相
- University of Kansas Medical Center, Westwood · 5マイル先
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
被験者募集中第1相
- University of Kansas Hospital-Westwood Cancer Center, Westwood · 5マイル先
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- University of Kansas Medical Center, Westwood · 5マイル先
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
被験者募集中第2/3相
- Premier Imaging, Kansas City
- St. Joseph Medical Center, Kansas City
- MidAmerica Cancer Care - American Oncology Partners, Kansas City
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
被験者募集中第1相
- The University of Kansas Medical Center, Westwood · 5マイル先
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
被験者募集中第3相
- HCA Midwest Kansas City, MidAmerica Division, Inc., Kansas City
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
被験者募集中第3相
- Saint Luke's Cancer Institute, Kansas City
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
被験者募集中第3相
- The University of Kansas Cancer Center - Westwood, Westwood · 5マイル先
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
被験者募集中第1/2相
- University of Kansas Cancer Center - North, Kansas City
- University of Kansas Hospital-Westwood Cancer Center, Westwood · 5マイル先
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
被験者募集中第3相
- University of Kansas Cancer Center - North, Kansas City
- University of Kansas Cancer Center, Westwood · 5マイル先
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
被験者募集中第3相
- Saint Luke's Cancer Institute, Kansas City
- The University of Kansas Cancer Center, Westwood · 5マイル先
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
被験者募集中第2/3相
- MidAmerica Cancer Care, Kansas City
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
被験者募集中第3相
- University of Kansas Cancer Center, Westwood · 5マイル先
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Kansas City
他の都市における転移性癌の試験
- Houston, TX104件の研究
- New York City, NY93件の研究
- Nashville, TN70件の研究
- Boston, MA63件の研究
- Los Angeles, CA57件の研究
- St. Louis, MO54件の研究
- Arlington, VA53件の研究
- Philadelphia, PA46件の研究
- Chicago, IL45件の研究
- San Antonio, TX44件の研究
- Washington, DC43件の研究
- Dallas, TX42件の研究
Kansas Cityにおける他の研究
- 乳がん34件の研究
- 非小細胞肺癌31件の研究
- 心不全25件の研究
- がん（全種類）21件の研究
- 肺がん19件の研究
- 大腸癌16件の研究
- 急性骨髄性白血病15件の研究
- 前立腺がん14件の研究
- 卵巣がん11件の研究
- 肥満症11件の研究
- 2型糖尿病11件の研究
- 心血管疾患11件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。